Melbourne-based Metabolic Pharmaceuticals (ASX:MBP) has reported a loss of AUD$10.7 million for the year ended 30 June 2005, up 13 per cent from $9.5 million last year. [ + ]

Biota Holdings' (ASX:BTA) US-based CEO Peter Molloy has decided not to renew his contract in January 2006 following the company's decision to consolidate its operations back into its Melbourne facility. [ + ]

Unlisted imaging company XRT, an investee of BioTech Capital (ASX:BTC), has secured new investment funds from a syndicate of UK investors including an undisclosed institutional group. [ + ]

Amrad (ASX:AML) has reported a healthy cash position of AUD$51.7 million and an operating loss of AUD$1.622 million for the year ended 30 June 2005, down from $3.523 million last year. [ + ]

Singapore-based generics company SciGen (ASX:SIE) has posted a net loss of SGD$5.6 million (AUD$4.43 million) for 2004-05, up 29 per cent from the previous financial year. [ + ]

Norwood Abbey (ASX:NAL) and Australian Wool Innovation (AWI) have signed an agreement to enter into phase II development of a non-surgical mulesing technology to prevent sheep flystrike using Norwood's needle-free injection technology. [ + ]

Australian corporate leader Hugh Morgan is the new chairman of Melbourne-based flu vaccine company BioDiem (ASX:BDM) which has reported an increased loss of AUD$4.2 million in 2004-05, up 32 per cent from the last financial year. [ + ]

NeuroSolutions, the UK based subsidiary of newly listed neurology-focused biotech company NeuroDiscovery (ASX:NDL) has identified and selected Sigma Aldrich to provide scale-up and manufacturing services in relation to its lead pain drug candidate, NSL-043, which is due to enter a phase I clinical trial later this year. [ + ]

Austin Health's new movement laboratory has been opened at the Royal Talbot Rehabilitation Centre in Kew, Melbourne to provide a clinical movement analysis service to assist people with disabilities to become more independent. [ + ]

Melbourne-based Acrux (ASX:ACR) posted revenue of AUD$4.8 million for the year ended June 30, 2005, up $1 million from the previous financial year, but also saw an increase in its net loss from $4.2 million in the previous year to $6 million in 2004-05. [ + ]

Ambri (ASX:ABI) saw a decrease in its revenue for the 2004-05 financial year of 27 per cent to $1 million (from $1.4 million in the previous year) but the company's loss was also down 22 per cent to $9 million. [ + ]

Sydney peptide therapeutics company Peptech (ASX:PTD) has reported positive results from a trial of a prostate cancer diagnostic developed by its joint-venture partner Biosceptre International. [ + ]

Gene therapy company Benitec (ASX:BLT) has weathered a head-on challenge from US rival, Nucleonics, to its key DNA-directed RNA-interference (ddRNAi) patents. [ + ]

Invitrogen has opened a AU$3.4 million cGMP bioproduction facility focused on the development of safe and consistent bovine sera products and reagents used in basic research and the production of vaccines and biotherapeutic drugs for world markets.

Australia's biggest biotech, Melbourne's CSL (ASX:CSL) has signed a license and option agreement with Merck & Co, granting the New Jersey-based pharmaceutical company certain rights and options to use CSL's Iscomatrix adjuvant in its pipeline of investigational vaccine products. [ + ]